Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness

Lancet

Volumn 367, Issue 9517, 2006, Pages 1173-1180

  Trunz, B Bourdin ^b   Fine, PEM ^b   Dye, C ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

AFRICA; ARTICLE; ASIA; BCG VACCINATION; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HUMAN; INFECTION RISK; META ANALYSIS; MILIARY TUBERCULOSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; TUBERCULOUS MENINGITIS; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH; INFANT; MALE; MORTALITY; PRESCHOOL CHILD; RISK FACTOR;

BCG VACCINE; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INFANT; MALE; RISK FACTORS; TUBERCULOSIS, MENINGEAL; TUBERCULOSIS, MILIARY; WORLD HEALTH;

EID: 33645989166     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68507-3     Document Type: Article

References (74)

1. Rodrigues L., Diwan V., and Wheeler J. Protective effect of BCG against TB meningitis and miliary TB: a meta-analysis. Int J Epidemiol 22 (1993) 1154-1158
2. Colditz G., Brewer T., Berkey C., et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271 (1994) 698-702
3. Comstock G. Field trials of tuberculosis vaccines: how could we have done them better?. Control Clin Trials 15 (1994) 247-276
4. Fine P. BCG vaccines and vaccination. In: Reichman L., and Hershfield E. (Eds). Tuberculosis: a comprehensive international approach (2001), Marcel Dekker, New York
5. Colditz G., Berkey C., Mosteller F., et al. The efficacy of Bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96 (1995) 29-35
6. Romanus V., Svensson A., and Hallander H. The impact of changing BCG coverage on tuberculosis incidence in Swedish-born children between 1969 and 1989. Tuber Lung Dis 73 (1992) 150-161
7. Romanus V., Hallander H., Wahlen P., Olinder-Nielsen A., Magnusson P., and Juhlin I. Atypical mycobacteria in extrapulmonary disease among children. Incidence in Sweden from 1969 to 1990, related to changing BCG- vaccination coverage. Tuber Lung Dis 76 (1995) 300-310
8. Trnka L., Dankova D., and Svandov E. Six years' experience with the discontinuation of BCG vaccination. 4. Protective effect of BCG vaccination against the Mycobacterium avium intracellulare complex. Tuber Lung Dis 75 (1994) 348-352
9. Ponnighaus J., Fine P., Sterne J., et al. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet 339 (1992) 636-639
10. Garly M., Bale C., Martins C., et al. BCG vaccination among West African infants is associated with less anergy to tuberculin and diphtheria-tetanus antigens. Vaccine 20 (2001) 468-474
11. Roth A., Jensen H., Garly M., et al. Low birth weight infants and Calmette-Guérin bacillus vaccination at birth: community study from Guinea-Bissau. Pediatr Infect Dis J 23 (2004) 544-550
12. Fine P., Carneiro I., Milstien J., and Clements C. Issues relating to the use of BCG in immunization programmes. A discussion document. WHO/V&B/99.23 (1999), WHO, Geneva 1-42
13. United Nations Population Division. World population prospects: the 2002 Revision (2002), United Nations, New York
14. WHO. Global tuberculosis control: surveillance, planning, financing (2005), World Health Organization, Geneva 247
15. National Center for Tuberculosis and Leprosy Control. National tuberculosis prevalence survey, 2002, Cambodia (2005), National Center for Tuberculosis and leprosy Control, Ministry of Health, Royal Government of Cambodia, Phnom Penh
16. Dye C., Scheele S., Dolin P., Pathania V., and Raviglione M. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA 282 (1999) 677-686
17. Corbett E., Watt C., Walker N., et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163 (2003) 1009-1021
18. Styblo K. The relationship between the risk of tuberculous infection and the risk of developing infectious tuberculosis. Bull Int Union Tuberc Lung Dis 60 (1985) 117-119
19. Styblo K. Epidemiology of Tuberculosis. 2nd edn. (1991), KNCV Tuberculosis Association, The Hague
20. Espinal M., Peréz E., Baéz J., et al. Infectiousness of Mycobacterium tuberculosis in HIV-1-infected patients with tuberculosis: a prospective study. Lancet 355 (2000) 275-280
21. Yamada N., Onozaki I., and Eang M. National TB Survey 2002, Cambodia: preliminary report of tuberculin survey. Tuberculosis Surveillance Research Unit Progress Report 2004 (2005), KNCV Tuberculosis Foundation, The Hague 40-48
22. Ministry of Public Health of the People's Republic of China. Nationwide random survey for the epidemiology of tuberculosis in 1990 (1990), Ministry of Public Health of the People's Republic of China, Beijing
23. Ministry of Health of the People's Republic of China. Report on Nationwide Random Survey for the Epidemiology of Tuberculosis in 2000 (2000), Ministry of Health of the People's Republic of China, Beijing
24. Tupasi T., Radhakrishna S., Rivera A., et al. The 1997 Nationwide Tuberculosis Prevalence Survey in the Philippines. Int J Tuberc Lung Dis 3 (1999) 471-477
25. Tupasi T., Radhakrishna S., Pascual M., et al. BCG coverage and the annual risk of tuberculosis infection over a 14-year period in the Philippines assessed from the Nationwide Prevalence Surveys. Int J Tuberc Lung Dis 4 (2000) 216-222
26. Hong Y., Kim S., Lew W., Lee E., and Han Y. The seventh nationwide tuberculosis prevalence survey in Korea, 1995. Int J Tuberc Lung Dis 2 (1998) 27-36
27. Odhiambo J., Borgdorff M., Kiambih F., et al. Tuberculosis and the HIV epidemic: increasing annual risk of tuberculous infection in Kenya, 1986-1996. Am J Public Health 89 (1999) 1078-1082
28. Tanzania Tuberculin Survey Collaboration. Tuberculosis control in the era of the HIV epidemic: risk of tuberculosis infection in Tanzania, 1983-1998. Int J Tuberc Lung Dis 5 (2001) 103-112
29. Egwaga S., Cobelens F., Muwinga H., and Borgdorff M. Tanzanian National Tuberculin Survey, 4th Round Results of Interim Analysis of 12 Regions. Tuberculosis Surveillance Research Unit Progress Report 2003-Volume II. The Hague: KNCV Tubercuclosis Foundation (2003) 107-122
30. Salaniponi F., Kwanjana J., Veen J., Misljenovic O., and Borgdorff M. Risk of infection with Mycobacterium tuberculosis in Malawi: national tuberculin survey 1994. Int J Tuberc Lung Dis 8 (2004) 718-723
31. Champetier de Ribes G., Ranaivoson G., Rakotoherisoa E., Andriamahefazafy B., and Blanchy S. [Annual risk of tuberculosis infection in Madagascar: study from 1991 to 1994]. Bull Soc Pathol Exot 90 (1997) 349-352
32. El Ibiary S., de Coster E., Tolba F., et al. Trend in the annual risk of tuberculous infection in Egypt, 1950-1996. Int J Tuberc Lung Dis 3 (1999) 294-299
33. Arnadottir T., Soukaseum H., Vangvichit P., Bounmala S., and Vos E. Prevalence and annual risk of tuberculosis infection in Laos. Int J Tuberc Lung Dis 5 (2001) 391-399
34. Chadha V., Agarwal S., Kumar P., et al. Annual risk of tuberculous infection in four defined zones of India: a comparative picture. Int J Tuberc Lung Dis 9 (2005) 569-575
35. Rieder H. Methodological issues in the estimation of the tuberculosis problem from tuberculin surveys. Tuber Lung Dis 76 (1995) 114-121
36. China Tuberculosis Control Collaboration. The effect of tuberculosis control in China. Lancet 364 (2004) 417-422
37. Behr M., Warren S., Salamon H., et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 353 (1999) 444-449
38. Styblo K., Meijer J., and Sutherland I. The transmission of tubercle bacilli. Bull Int Union Tuberc Lung Dis 42 (1969) 1-73
39. Styblo K., and Sutherland I. Epidemiology of tuberculosis in children. Bull Int Union Tuberc Lung Dis 57 (1982) 133-139
40. de March-Ayuela P. Trend in tuberculous meningitis in Barcelona children aged 0-4 years: correlation with the annual risk of tuberculous infection. Tuber Lung Dis 75 (1994) 423-428
41. Spyridis P., Tsolia M., Gelesme A., et al. The impact of Greece's childhood tuberculosis screening programme on the epidemiological indexes in the greater Athens area. Int J Tuberc Lung Dis 7 (2003) 248-253
42. Snider Jr. D., Rieder H., Combs D., Bloch A., Hayden C., and Smith M. Tuberculosis in children. Pediatr Infect Dis J 7 (1988) 271-278
43. Hussey G., Chisholm T., and Kibel M. Miliary tuberculosis in children: a review of 94 cases. Pediatr Infect Dis J 10 (1991) 832-836
44. Lobato M., Cummings K., Will D., and Royce S. Tuberculosis in children and adolescents: California, 1985 to 1995. Pediatr Infect Dis J 17 (1998) 407-411
45. World Health Organization. Vaccines, Immunization and Biologicals. Statistics and Graphics. http://www.who.int/vaccines-surveillance/StatsAndGraphs.htm (accessed Sept 21, 2005)
46. World Health Organization. BCG in immunization programmes. Wkly Epidemiol Rec 76 (2001) 33-40
47. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet 19 (1955) 251-253
48. Miceli I., De Kantor I., Colai covo D., et al. Evaluation of the effectiveness of BCG vaccination using the case-control method in Buenos Aires, Argentina. Int J Epidemiol 17 (1988) 629-634
49. Costa Mda C., Mota E., and Pinto L. Protective effect of intradermal BCG on tuberculous meningitis. Bol Oficina Sanit Panam 110 (1991) 26-32
50. Wunsch Filho V., de Castilho E., Rodrigues L., and Huttly S. Effectiveness of BCG vaccination against tuberculous meningitis: a case-control study in Sao Paulo, Brazil. Bull World Health Organ 68 (1990) 69-74
51. Wunsch-Filho V., Moncau J., and Nakao N. Methodological considerations in case-control studies to evaluate BCG vaccine effectiveness. Int J Epidemiol 22 (1993) 149-155
52. Camargos P., Guimaraes M., and Antunes C. Risk assessment for acquiring meningitis tuberculosis among children not vaccinated with BCG: a case-control study. Int J Epidemiol 17 (1988) 193-197
53. Myint T., Win H., Aye H., and Kyaw-Mint T. Case-control study on evaluation of BCG vaccination of newborn in Rangoon, Burma. Ann Trop Paediatr 7 (1987) 159-166
54. Zodpey S., Maldhure B., Dehankar A., and Shrikhande S. Effectiveness of Bacillus Calmette-Guérin (BCG) vaccination against extra-pulmonary tuberculosis: a case-control study. J Indian Med Assoc 94 (1996) 338-341
55. Thilothammal N., Krishnamurthy P., Runyan D., and Banu K. Does BCG vaccine prevent tuberculous meningitis?. Arch Dis Child 74 (1996) 144-147
56. Mittal S., Aggarwal V., Rastogi A., and Saini N. Does BCG vaccination prevent or postpone the occurrence of tuberculous meningitis?. Indian J Paediatr 63 (1996) 659-664
57. Sharma R., Srivastava D., Asunkanta Singh A., et al. Epidemiological evaluation of BCG vaccine efficacy in Delhi-1989. J Commun Dis 21 (1989) 200-206
58. Awasthi S., and Moin S. Effectiveness of BCG vaccination against tuberculous meningitis. Indian Pediatr 36 (1999) 455-460
59. Murtagh K. Efficacy of BCG. Lancet 315 (1980) 423
60. Bhattacharjee J., Sharma R., Singh J., Datta K., and Verghese T. Case series evaluation of BCG vaccine efficacy against tubercular meningitis in children in Delhi. J Commun Dis 25 (1993) 71-74
61. Putrali J. A case-control study of the effectiveness of BCG vaccination in children in Jakarta, Indonesia. Proc East Reg Tuberc Conf Int Union Tuberc 99 (1983) 194-220
62. Barnum H. Cost savings from alternative treatments for tuberculosis. Soc Sci Med 23 (1986) 847-850
63. Pathania V., Trnka L., Krejbich F., and Dye C. A cost-benefit analysis of BCG revaccination in the Czech Republic. Vaccine 17 (1999) 1926-1935
64. Schaaf H., Gie R., and Beyers N. Tuberculosis in childhood. In: Davies P. (Ed). Clinical tuberculosis. 3rd edn. (2004), Arnold, London 154-168
65. WHO. The World Health Report 2004: Changing History (2004), World Health Organization, Geneva
66. Jamison D. Disease control priorities in developing countries: an overview. In: Jamison D., Mosley W., Meashem A., and Bobadilla J. (Eds). Disease Control Priorities in Developing Countries (1993), Oxford University Press for the World Bank, New York 3-34
67. Garber A., and Phelps C. Economic foundations of cost-effectiveness analysis. J Health Econ 16 (1997) 1-31
68. In: Jamison D., Mosley W., Meashem A., and Bobadilla J. (Eds). Disease Control Priorities in Developing Countries (1993), Oxford University Press for the World Bank, New York
69. Murray C., De Jonghe E., Chum H., Nyangulu D., Salomao A., and Styblo K. Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet 338 (1991) 1305-1308
70. Dye C, Floyd K. Tuberculosis. In: Jamison DT, Alleyne GAO, Breman JG, et al., eds. Disease Control Priorities in Developing Countries, 2nd edn. Washington DC: Oxford University Press (in press).
71. Fine P. Stopping routine vaccination for tuberculosis in schools. BMJ 331 (2005) 647-648
72. International Union Against Tuberculosis and Lung Disease. Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guérin (BCG) in countries with a low prevalence of tuberculosis: a statement of the International Union Against Tuberculosis and Lung Disease. Tuber Lung Dis 75 (1994) 179-180
73. Aronson N., Santosham M., Comstock G., et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60-year follow-up study. JAMA 291 (2004) 2086-2091
74. Garly M., Martins C., Bale C., et al. BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG?. Vaccine 21 (2003) 2782-2790